Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

Open Access 26-10-2023 | Abdominal Aortic Aneurysm | Brief Report

Increased recognition of Q fever aortitis as a chronic manifestation of Q fever in tropical North Queensland, Australia

Authors: Cody Price, Simon Smith, James Stewart, Tom Palesy, Matthew Corbitt, Charith Galappaththy, Josh Hanson

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2023

Abstract

Aortitis is a life-threatening, manifestation of chronic Q fever. We report a series of 5 patients with Q fever aortitis who have presented to our hospital in tropical Australia since 2019. All diagnoses were confirmed with polymerase chain reaction (PCR) testing of aortic tissue. Only one had a previous diagnosis of acute Q fever, and none had classical high-risk exposures that might increase clinical suspicion for the infection. All patients underwent surgery: one died and 3 had significant complications. Q fever aortitis may be underdiagnosed; clinicians should consider testing for Coxiella burnetii in people with aortic pathology in endemic areas.

Raoult D, Tissot-Dupont H, Foucault C, Gouvernet J, Fournier PE, Bernit E et al (2000) Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. Medicine 79(2):109–23 (Baltimore)CrossRefPubMed

Australian Immunisation Handbook (2021) Q fever. Canberra: Australian Government. Department of Health and Aged Care. https://immunisationhandbook.health.gov.au/contents/vaccine-preventablediseases/q-fever

Tozer S, Wood C, Si D, Nissen M, Sloots T, Lambert S (2020) The improving state of Q fever surveillance. A review of Queensland notifications, 2003–2017. Commun Dis Intell 2018:44. https://doi.org/10.33321/cdi.2020.44.48

Sloan-Gardner TS, Massey PD, Hutchinson P, Knope K, Fearnley E (2017) Trends and risk factors for human Q fever in Australia, 1991–2014. Epidemiol Infect 145(4):787–795CrossRefPubMed

Kampschreur LM, Delsing CE, Groenwold RH, Wegdam-Blans MC, Bleeker-Rovers CP, de Jager-Leclercq MG et al (2014) Chronic Q fever in the Netherlands 5 years after the start of the Q fever epidemic: results from the Dutch chronic Q fever database. J Clin Microbiol 52(5):1637–1643CrossRefPubMedPubMedCentral

Graves SR, Islam A, Webb LD, Marsh I, Plain K, Westman M et al (2022) An O-specific polysaccharide/tetanus toxoid conjugate vaccine induces protection in guinea pigs against virulent challenge with Coxiella burnetii. Vaccines (Basel) 10(9):1393. https://doi.org/10.3390/vaccines10091393

Eldin C, Melenotte C, Mediannikov O, Ghigo E, Million M, Edouard S et al (2017) From Q fever to Coxiella burnetii infection: a paradigm change. Clin Microbiol Rev 30(1):115–190CrossRefPubMed

Eldin C, Mailhe M, Lions C, Carrieri P, Safi H, Brouqui P et al (2016) Treatment and prophylactic strategy for Coxiella burnetii infection of aneurysms and vascular grafts: a retrospective cohort study. Medicine 95(12):e2810 (Baltimore)CrossRefPubMedPubMedCentral

Wegdam-Blans MC, Kampschreur LM, Delsing CE, Bleeker-Rovers CP, Sprong T, van Kasteren ME et al (2012) Chronic Q fever: review of the literature and a proposal of new diagnostic criteria. J Infect 64(3):247–259CrossRefPubMed

Title: Increased recognition of Q fever aortitis as a chronic manifestation of Q fever in tropical North Queensland, Australia
Authors: Cody Price
Simon Smith
James Stewart
Tom Palesy
Matthew Corbitt
Charith Galappaththy
Josh Hanson
Publication date: 26-10-2023
Publisher: Springer Berlin Heidelberg
Keywords: Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Polymerase Chain Reaction
Aortic Aneurysm
Aortic Aneurysm
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2023
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-023-04687-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2023

Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis

Country-wide expansion of a VIM-1 carbapenemase-producing Klebsiella oxytoca ST145 lineage in Poland, 2009–2019

Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life

Effectiveness of a multimodal intervention to improve blood culture collection in an adult emergency department

Co-regulation of biofilm formation and antimicrobial resistance in Acinetobacter baumannii: from mechanisms to therapeutic strategies

Amino acid substitutions in the region between RpoB clusters II and III on rifampin susceptibility in Haemophilus influenzae

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials